Exploring the promising potential and challenges of organoids in esophagus and esophageal squamous cell carcinoma research Esophageal squamous cell ...

Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive ...

However, traditional clinical trial designs are often ill-suited for rare disease research with common challenges including ...

MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first ...

MindRank doses first patient in phase III clinical trial of AI-designed oral GLP-1 receptor agonist, MDR-001: Shanghai Saturday, February 28, 2026, 18:00 Hrs [IST] MindRank, a cli ...

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered ...

Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.

Psychedelic drug development can still benefit from the FDA Commissioner’s National Priority Review Voucher Pilot Program, though the CNPV designation was not given to Compass Pathways’ synthetic ...

The FDA has released draft guidance on how sponsors can use Bayesian models for clinical trials.

Ruthie Davi, vice president of statistics and regulatory innovation at Medidata, highlights the value of technology in rare ...

Operator: Good morning. Welcome to the Aurinia Pharmaceuticals Fourth Quarter and Full Year 2025 Conference Call. Please be ...

Why Kashmir Pays More For Medicines Than The Rest Of India. IN many homes across Jammu and Kashmir, the pharmacy bill has become as routine as the electricity bill. The difference is that it keeps ...